Hospital Formulary Insights

September 2013

Hospital Formulary Insights® : Anti-Infectives (US) 2013

Introduction:

Despite heavy generic competition, antibiotic hospital market continues to provide commercial opportunities for novel therapies, especially for agents with activity against drug-resistant pathogens such as methicillin-resistant Staphylococcus aureus (MRSA) and multi-drug resistant Gram-negative pathogens. Earning a favorable status on the hospital formulary is imperative for emerging therapies vying to gain access to the hospital market.
This study provides an in-depth view of the hospital formulary decision-making process for antibacterial therapies in the United States. Through primary market research with hospital pharmacy directors and infectious diseases specialists who serve on their hospitals’ pharmacy and thera-peutics (P&T) committees, we are able to understand the influence of cost factors, clinical factors, and product attributes on antibiotic formulary deci-sions. The study also provides proprietary historical data on hospital for-mulary inclusion for current therapies, as well as an analysis of anticipat-ed inclusion of emerging antibiotics by P&T committee members.

Questions Answered in This Report:

  *   What is the overall structure of the P&T committees? Who are the key stakeholders and influencers for sales force targeting?


  *   What factors influence formulary decision-making? What is the rela-tive importance of drug-specific attributes and pharmacoeconomic data in driving or constraining formulary inclusion?


  *   What are clinical and administrative challenges for formulary approval of new products?


  *   Are there any ongoing or planned changes to the current hospital formulary?


  *   How has formulary status of key agents evolved in the last ten years? How successfully have recently-launched Teflaro and Dificid penetrat-ed hospital formularies?


  *   What is the current formulary, stocking and restriction status of all currently marketed antibacterial brands?


  *   How will P&T committees evaluate emerging therapies and what is the anticipated formulary status of novel agents?


  *   Which key sales force and drug manufacturer/marketer messages resonate with the P&T committee?

Scope:

Sample Frame & Methodology:

- ~100 hospital-based infectious diseases (ID) specialists and pharmacy directors complete a 30-minute online quantitative survey with several open-ended questions for qualitative feedback.

To qualify, respodents must meet the following criteria:

- Active and current member of their hospital P&T committee

- Have been in practice a minimum of 2 years and a maximum of 30 years

- More than 50 percent of professional time spent in clinical practice in the hospital setting

Deliverables:

- Final report in PowerPoint format

- Complete set of frequency tables, summary statistics and standard cross tabulations

Key Drugs Covered:

- Doribax (doripenem), Invanz(ertapenem), Teflaro (ceftaroline), Zyvox (linezolid), Cubicin (daptomycin), Vibativ (telavancin), Tygacil (tigecycline), Dificid (fidaxomicin), key generic competi-tion, and emerging therapies in late-stage development, including tedizolid, CXA-201, and CAZ-AVI

Report Dates:

- Publish: September 2013

Research with Physicians and Pharmacy Directors:

- 100 hospital-based infectious diseases specialists and hospital pharmacy directors who currently sit on their hospital P&T committee

Geographies:

- United States

Key Companies Mentioned:

- Astellas

- AstraZeneca

- Cubist

- Forest Laboratories

- Merck

- Pfizer

- Theravance

- Trius Therapeutics

Content Highlights:

- Primary market research with hospital P&T committees

- Current formulary status and key restrictions for antibiotics

- Ten years of historical formulary data from AMR’s proprietary hospital formulary database

- Historical drug stocking data

- Influence of cost assessments on formulary decisions

- Process for formulary uptake

- Unmet needs and product differentiation

- Emerging therapies

- Strategic, actionable recom-mendations for optimizing market access

Related Reports:

- Hospital Formulary Insights®: Antibiotics (EU)

- TreatmentTrends®: Gram Negative Infections (US)

- TreatmentTrends®: MRSA and Serious Gram-Positive Infections (US)

- TreatmentTrends®: Clostridium Difficile Infections (EU)

- DecisionBase®: Hospital-Acquired Pneumonia

- DecisionBase®: Clostridium Difficile Infections

- PatientBase®: Hospital-Treated Infections in the G7

- Pharmacor®: Hospital-Treated Infections

- Pharmacor®: MRSA Infections

- Physician And Payer Forum®: Gram-Negative Infections (US)

- Physician And Payer Forum®: Outpatient Parenteral Antimicrobial Thera-py (OPAT) for Skin Infections and Osteomyelitis (US)

Fill out the form below to contact sales.

Search Reports

Decision Resources Group brands include: